The TGA has approved the photoprotective drug afamelanotide for prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The subcutaneous implant under the brand name Scenesse is used to increase pain-free light exposure in people affected by the rare inherited metabolic disorder of haem molecule synthesis resulting from overproduction of protoporphyrin IX (PPIX). Afamelanotide ...
Photoprotective drug approved for use in EPP patients
By Michael Woodhead
27 Nov 2020